119 related articles for article (PubMed ID: 2295112)
1. Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.
Sundman-Engberg B; Tidefelt U; Liliemark J; Paul C
Cancer Chemother Pharmacol; 1990; 25(4):252-6. PubMed ID: 2295112
[TBL] [Abstract][Full Text] [Related]
2. Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo.
Sundman-Engberg B; Tidefelt U; Gruber A; Paul C
Leuk Res; 1993 Apr; 17(4):347-52. PubMed ID: 8487583
[TBL] [Abstract][Full Text] [Related]
3. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations.
Tidefelt U; Sundman-Engberg B; Rhedin AS; Paul C
Eur J Haematol; 1989 Nov; 43(5):374-84. PubMed ID: 2482193
[TBL] [Abstract][Full Text] [Related]
4. Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.
Tidefelt U; Sundman-Engberg B; Paul C
Cancer Chemother Pharmacol; 1991; 29(1):7-12. PubMed ID: 1742852
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
Paul C; Liliemark J; Tidefelt U; Gahrton G; Peterson C
Ther Drug Monit; 1989; 11(2):140-8. PubMed ID: 2718219
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.
Tidefelt U; Sundman-Engberg B; Paul C
Cancer Chemother Pharmacol; 1989; 24(4):225-9. PubMed ID: 2752502
[TBL] [Abstract][Full Text] [Related]
7. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
8. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
[TBL] [Abstract][Full Text] [Related]
11. [Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C].
Kamiya K; Uchida M; Ueda T; Nakamura T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1419-27. PubMed ID: 2212834
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
Kishi S; Goto N; Nakamura T; Ueda T
Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
[TBL] [Abstract][Full Text] [Related]
13. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
[TBL] [Abstract][Full Text] [Related]
14. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Hug V; Keating MJ; Chubb S
Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells.
Rhedin AS; Tidefelt U; Jönsson K; Lundin A; Paul C
Leuk Res; 1993 Mar; 17(3):271-6. PubMed ID: 7680736
[TBL] [Abstract][Full Text] [Related]
17. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
19. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Crews KR; Gandhi V; Srivastava DK; Razzouk BI; Tong X; Behm FG; Plunkett W; Raimondi SC; Pui CH; Rubnitz JE; Stewart CF; Ribeiro RC
J Clin Oncol; 2002 Oct; 20(20):4217-24. PubMed ID: 12377965
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
Yamauchi T; Kawai Y; Kishi S; Goto N; Urasaki Y; Imamura S; Fukushima T; Yoshida A; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
